Safety of pegfilgrastim in children [3]

Annals of Pharmacotherapy

Volumn 42, Issue 2, 2008, Pages 290-

  André, Nicolas ^a   Milano, Emilie ^a   Rome, Angelique ^a   Gentet, Jean Claude ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; AGED; CHILD; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; SECOND CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR;

EID: 39049105783     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K524     Document Type: Letter

References (5)

1. Snyder RL, Stringham DJ. Pegfilgrastim-induced hyperleukocytosis. Ann Pharmacother 2007;41:1524-30. Epub 31 Jul 2007. DOI 10.1345/aph.1K093
2. André N, Kababri ME, Bertrand P, et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007; 18:277-81.
3. te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES. Pegfilgrastim in pediatric cancer patients. J Pediatric Hematol Oncol 2005;27:627-9.
4. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005;27:449-51.
5. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 2006;19:3187-205.